NAD+ (injectable)

Stated plainly and neutrally, exactly as you'll hear it. We grade each one below.

• Marketed to raise cellular NAD+, a coenzyme central to mitochondrial energy (ATP) production and DNA repair that declines with age.
• Promoted for energy, mental clarity, reduced brain fog, mood, and addiction/withdrawal support.
• IV/injectable routes are pitched as bypassing poor oral absorption to deliver NAD+ 'directly' to the bloodstream.
• Positioned as a longevity / 'cellular reset' intervention by wellness and anti-aging clinics.

The honest test: if it's working, is there any objective way to see it, a blood marker, a scan, a wearable? For a lot of peptides the answer is no, and that's worth knowing before you spend on labs or gear.

ASSUMED mechanism: NAD+ is an essential coenzyme for mitochondrial ATP production, redox reactions, and as a substrate for DNA-repair enzymes (PARPs) and sirtuins; tissue NAD+ falls with age, so the theory is that injecting NAD+ replenishes it. The human PK data complicate this: infused NAD+ is rapidly cleared and substantially cleaved to nicotinamide and ADP-ribose extracellularly, meaning cells likely take up the breakdown products and resynthesize NAD+ internally rather than importing intact NAD+. So even if benefits occur, the proposed 'direct cellular refill' picture is largely assumed and partly contradicted by the data.

Anecdote, not proof, weighted because the science is thin. Here's the record, graded on volume, consistency, and how credible the sources are.

• Many users report a noticeable lift in energy, mental clarity, and reduced brain fog in the days after a session or loading series, though some say the effect fades within days to a couple of weeks (anecdotal, not proof).
• A very common refrain is that the infusion itself feels rough: chest pressure/tightness, nausea, cramping, and a racing heart if run too fast, with people emphasizing that slowing the drip way down is what makes it tolerable (anecdotal).
• In addiction-recovery communities, users often credit IV NAD+ with easing withdrawal symptoms, cravings, and mood during early sobriety, frequently as part of a broader treatment program, which confounds attribution (anecdotal).
• A skeptical contingent reports little durable benefit beyond feeling hydrated and 'pampered,' and questions whether the high per-session cost justifies effects they suspect are largely placebo (anecdotal).

1. 1961Dr. Paul O'Hollaren (Shadel Hospital, Seattle) publishes an uncontrolled case series using IV NAD+ in 100+ addiction cases; notes headache and shortness of breath at faster drip rates, the first description of rate-dependent infusion reactions.
2. 2010sIV NAD+ ('NAD therapy', 'the NAD drip') spreads through addiction-recovery and concierge wellness clinics; aggressive longevity/energy marketing despite no controlled outcome data.
3. 2019Grant et al. pilot PK study (n=11) shows infused NAD+ is cleared from plasma for the first 2 hours and largely metabolized to nicotinamide and ADP-ribose, the first hard human evidence that IV NAD+ is mostly broken down, not delivered intact.
4. 2024First randomized, placebo-controlled acute pilot (NCT06382688) directly compares IV NAD+ to IV NR: NAD+ raises blood NAD+ less, is less tolerable, slower to infuse, and shows a WBC/neutrophil rise.
5. 2025-2026Retrospective tolerability pilot and PRISMA-guided reviews reaffirm: every IV NAD+ patient had moderate-to-severe infusion symptoms, and controlled OUTCOME evidence for anti-aging/wellness remains absent.
6. Jul-Oct 2025A compounder begins a voluntary recall of NAD+ injection on Jul 30 2025; in October 2025 FDA classifies it Class I for elevated endotoxin.
7. Sep 2025 / Jan 2026Yu et al. publish a 180-patient randomized placebo-controlled trial of IV NAD+ (10 mg a day for 7 days) in ischemic heart failure: ejection fraction improves at one month. The first outcomes RCT of injectable NAD+, in a disease population.
8. Jan 20 2026FDA warning letter to an NAD+ compounder states NAD+ is not on the 503B bulks list.

Cross-checked across a 2019 PK pilot (PMC6751327), a 2024 randomized placebo-controlled acute pilot (NCT06382688), a 2025-2026 retrospective tolerability pilot (PMC12907335), PRISMA/systematic reviews, and regulatory/FDA compounding guidance. Findings are strikingly consistent: IV NAD+ exists and is broadly survivable but is largely degraded en route, less efficient and less tolerable than IV NR, and unsupported by any anti-aging or wellness outcome RCT; the one outcomes trial (Yu 2026, heart failure, 10 mg a day) is a disease surrogate. Note: the strongest head-to-head dataset comes from the NR supplement-industry sphere, so its 'NR is superior' framing is an interested conclusion, but the underlying data on injectable NAD+ are independent of that spin.

• Grant et al. (2019). Human plasma & urine NAD+ metabolome during 6-h IV NAD+ infusion (PMC6751327) ↗· Foundational human PK pilot (n=11): infused NAD+ cleared from plasma for first 2 h and largely cleaved to nicotinamide/ADP-ribose. Best evidence that IV NAD+ is mostly degraded en route.
• Acute randomized placebo-controlled pilot: IV NR vs IV NAD+ vs oral NR vs saline (NCT06382688) ↗· Acute RCT directly testing IV NAD+ (53 participants, preprint only: doi 10.1101/2024.06.06.24308565). Surrogate endpoint (blood NAD+), not clinical outcome; IV NAD+ less effective/less tolerable than NR, with a WBC/neutrophil rise. Industry-adjacent, read framing critically.
• IV NAD+ vs NR retrospective tolerability pilot, Frontiers in Aging (PMC12907335) ↗· Real-world pilot: 100% of IV NAD+ recipients had moderate-to-severe infusion symptoms; ~97 min infusions. Small, retrospective.
• Gallagher and Emmanuel, Ageing Res Rev 2026 (PMID 41655607) ↗· PRISMA review of 113 studies: no eligible outcomes trials of IV or IM NAD+ for anti-aging or wellness; effectiveness for those uses is inconclusive.
• Yu et al., Am J Cardiovasc Drugs 2026 (PMID 40954388) ↗· 180-patient placebo-controlled RCT of IV NAD+ 10 mg a day for 7 days in ischemic cardiomyopathy; LVEF higher at one month (p=0.024). Single-center, surrogate endpoint, disease population.
• FDA: compounders must use ingredients suitable for sterile compounding (NAD+) ↗· Injectable NAD+ is not FDA-approved. FDA has warned against food-grade NAD+ for IV use (contamination/AE risk).
• FDA warning letter 718739 to an NAD+ compounder, Jan 20 2026 ↗· States NAD+ is not on the 503B bulks list; documents an endotoxin-contaminated lot and a Class I recall.